RPE65 and Leber congenital amaurosis: Furthermore, the first viral gene therapy (Luxturna; voretigene neparvovec) gained FDA approval in 2018 for treating Leber congenital amaurosis (LCA) type 2, caused by mutations in RPE65 [2].